Navigation Links
Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia
Date:1/14/2009

New treatment option for the estimated 6 million Americans living with this chronic, debilitating condition

NEW YORK and SAN DIEGO, Jan. 14, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) today announced that Savella(TM) (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function, afflicting as many as six million people in the United States. The safety and efficacy of Savella was established in two US pivotal phase III clinical trials involving over 2,000 patients with fibromyalgia. The studies showed that Savella doses of 100 mg/day and 200 mg/day demonstrated statistically significant and clinically meaningful concurrent improvements in pain, patient global assessment, and physical function. The companies expect Savella to be available in pharmacies by March 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

"Fibromyalgia is a complicated chronic pain condition, so it is important that physicians and patients have access to treatments that have been shown to help manage the symptoms that define the experience of fibromyalgia," said Dr. Daniel Clauw, Professor of Anesthesiology and Medicine (Rheumatology) at the University of Michigan. "The introduction of Savella is important because it is the first drug approved to treat the symptoms of fibromyalgia using a composite responder analysis.".

"Savella is the
'/>"/>

SOURCE Forest Laboratories, Inc.; Cypress Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings
2. Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares
3. Forest Laboratories Responds To Unsolicited Mini-Tender Offer
4. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
5. Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
6. Wake Forest researchers say popular fish contains potentially dangerous fatty acid combination
7. Lake Forest, CA: SpeechPhone Launches Handsfree Driving Solution Just in Time to Comply with New Handsfree Driving Laws
8. Wake Forest Class Taps Recordant for Web-Based Search and Playback of Course Materials
9. Cleaner Air May Threaten Amazon Rainforest
10. Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment
11. Metrologic and Wake Forest University Baptist Medical Center Sponsored Healthcare Educational Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 Many ... for people’s health. Mercola.com has introduced organic cotton ... contain toxic flame retardant chemicals. Dr. Mercola’s Healthy ... design and better materials. Organic cotton is significantly ... Mercola’s organic bedding products are made by Naturepedic ...
(Date:2/27/2015)... NewYork (PRWEB) February 27, 2015 ... study that presents the analysis of the cell ... The research report discusses the current scenario and ... surface coating industry for the period of 2015 ... @ http://www.researchmoz.us/global-cell-culture-protein-surface-coating-market-2015-2019-report.html , The research report, ...
(Date:2/27/2015)... Summit County, CO (PRWEB) February 27, 2015 ... Kevin and Amy Smits help to restore ... year for the last six years, this husband/wife Realtor team ... of the charities have remained the same while others have ... Victims of Assault provides a safe haven and counseling ...
(Date:2/27/2015)... February 27, 2015 Qualis Health, ... organizations, has been named a finalist in the ... recognition of outstanding commitment toward continuous improvement in ... in reducing hospital readmission rates through its Communities ... are honored to receive this national recognition, which ...
(Date:2/27/2015)... 27, 2015 Jvion announced today ... collaborating with the Atlanta-based software company through a ... Jvion’s advanced predictive capabilities suite within the provider ... identifies and prevents financial and clinical losses within ... that help prevent patient deterioration and suffering, the ...
Breaking Medicine News(10 mins):Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 2Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 3Health News:Mr. And Mrs. Smits Proves That Altruism Works All Year Round 2Health News:Qualis Health Named Award Finalist for Care Transitions Work 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 3
... fatigue in subjects whether or not they have a head ... period of time can induce fatigue," said Semyon Slobonouv, professor ... symptom of concussion. How do you rule out fatigue ... way to test patients for concussion is to use an ...
... -- A gene mutation that helps clear fat from the ... if people with this mutation have a lower risk of ... Netherlands studied two families with unusually high levels of "good" ... fat that circulates in the blood. Genetic sequencing revealed that ...
... from the CHUQ research center and Universit Laval have ... neurological disorder that affects more than 10 million North ... recent edition of the scientific journal Brain . ... most common involuntary movement disorder. An estimated 4% of ...
... protein in the human body is undeniable. However, the idea ... as easy to determine. A new study from the ... at the criteria for determining the quality of a protein. ... such as milk and eggs to be high in quality. However, ...
... become both safer and more realistic thanks to research ... Australia. Professor Dietmar W. Hutmacher from QUT,s Institute ... research project in collaboration with engineers and surgeons in ... to produce moulds accurately modelled on a laser scan ...
... coverage increased dramatically in parts of China between 1997 ... to improve access to health care, with particularly striking ... Brown University sociologist Susan E. Short and Hongwei Xu ... the December issue of Health Affairs . ...
Cached Medicine News:Health News:Concussion testing makes everyone tired 2Health News:Gene Mutation Helps Clear Fats From Blood, Study Finds 2Health News:Soy is on top as a high-quality plant protein 2Health News:Research advances breast reconstruction 2Health News:Chinese health coverage increases with new government efforts 2Health News:Chinese health coverage increases with new government efforts 3
(Date:2/27/2015)... CARLSBAD, Calif., Feb. 27, 2015 Isis Pharmaceuticals, ... significantly outperformed both its pro forma net operating loss ... in a strong financial position.  Isis, significantly improved financial ... than $230 million in payments the Company received from ... for 2014 was a nearly 60% improvement over its ...
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
(Date:2/27/2015)... PLAINFIELD, N.J., Feb. 27, 2015  PTC Therapeutics, Inc. ... update and reported financial results for the fourth quarter ... "2014 was a transformative year for PTC. We ... delivering and developing RNA-targeted therapies in the rare disease ... PTC Therapeutics, Inc. "We are proud to bring the ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
... A unique treatment involving the use of hot chemotherapy ... Center. SJH&MC is the first hospital in Southeast Michigan ... offer the treatment. Know as Hyperthermic Intraperitoneal ... number of advanced cancers that have spread to the ...
... and SYDNEY, Nov. 4, 2011 HeartWare International, Inc. ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that CEO Doug Godshall is scheduled to ... 11:00 a.m. MST on Wednesday, November 9, 2011.  The ...
Cached Medicine Technology:St. John Hospital 1st in Region to Offer Innovative Chemotherapy Delivery System 2HeartWare to Present at the Credit Suisse 2011 Healthcare Conference 2
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... concave seats and large backrests with lumbar ... armrests, and casters and glides. • Choose ... a variety of environments including: industry, education, ... and office. • With tubular base • ...
Medicine Products: